INS and Insulin resistance: Insulin sensitisers such as thiazolidinediones and metformin have been trialled but results from randomised clinical trials in HIV patients have shown mixed results.19, 20 Moreover, the associated adverse effects may limit their use in HIV-infected patients.21, 22 Therefore, there is a need for novel clinical interventions with proven safety profile that can reduce cART-induced insulin resistance in HIV-infected individuals.